Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Carolyn Young's publication output changed over time?
ScholarIQpublication output · 1999–2019
Output grew0% over the shown period — from 1 works in 1999 to 1 in 2019.
1
1
1
2
1
1
2
1
1
199920032005200720092014201520182019
What are the most-cited papers on Carolyn Young?
ScholarIQmost cited works
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
David Rog, Turo Nurmikko, Tim Friede, Carolyn Young
Neurology. 2005680 Citations
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
Gıancarlo Comı, Vittorio Martinelli, M. Rodegher, Lucia Moiola, Ovidiu Băjenaru, Adriana Carrá, Irina Elovaara, Franz Fazekas, HP Hartung, Jan Hillert, John King, Sámuel Komoly, Catherine Lubetzki, Xavier Montalbán, K-M Myhr, Mads Ravnborg, P Rieckmann, Daniel Wynn, Carolyn Young, Massimo Filippi
The Lancet. 2009588 Citations
Achieving Saturation in Thematic Analysis: Development and Refinement of a Codebook
Hikari Ando, Rosanna Cousins, Carolyn Young
Comprehensive Psychology. 2014579 CitationsOPEN ACCESS
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L. Arnold, Mark S. Freedman, Myla Goldman, Hans-Peter Hartung, Eva Havrdová, Douglas Jeffery, A Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, E Bartholomé, Marie D’hooghe, Massimo Pandolfo, Bart Van Wijmeersch, Virender Bhan, Gregg Blevins, Donald Brunet, Virginia Devonshire, Pierre Duquette, Mark S. Freedman, François Grand’Maison, François Jacques, Yves Lapierre, Liesly Lee, Sarah A. Morrow, Michael Yeung, Michal Dufek, Eva Havrdová, Petr Kaňovský, Ivana Štětkářová, Marika Talábová, Jette Lautrup Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, Finn Sellebjerg, Laura Airas, Irina Elovaara, Juha-Pekka Erälinna, Taneli Sarasoja, Abdullatif Al Khedr, David Brassat, Bruno Brochet, William Camu, Marc Debouverie, David Laplaud, Christine Lebrun‐Frénay, Jean Pelletier, Patrick Vermersch, Sandra Vukusi, Karl Baum, Achim Berthele, Juergen Faiss, Peter Flachenecker, Reinhard Hohlfeld, Markus Krumbholz, Christoph Lassek, Mathias Maeurer, Sven G. Meuth, Tjalf Ziemssen, Orla Hardiman, Christopher McGuigan, Anat Achiron, Dimitrios Karussis, Roberto Bergamaschi, Vincenzo Brescia Morra, Giancarlo Comi, Salvatore Cottone, Luigi M.E. Grimaldi, Giovanni Luigi Mancardi, Luca Massacesi, Ugo Nocentini, Marco Salvetti, Elio Scarpini, Patrizia Sola, Gioacchino Tedeschi, María Trojano, Mauro Zaffaroni, Stephan Frequin, Raymond Hupperts, Joep Killestein, Hans M. Schrijver, Ronald Van Dijl, Erik van Munster, Maciej Czarnecki, Wiesław Drozdowski, Waldemar Fryze, Hanka Hertmanowska, Jan Ilkowski, Anna Kamińska, Gabriela Kłodowska-Duda
S70053155. 2018344 CitationsOPEN ACCESS
The effect of anti-α4 integrin antibody on brain lesion activity in MS
Niall Tubridy, P. O. Behan, Rudy Capildeo, Abhijit Chaudhuri, Raeburn B Forbes, Philip N. Hawkins, Richard AC Hughes, Jacqueline Palace, Basil Sharrack, Robert Swingler, Carolyn Young, I. F. Moseley, David MacManus, Stephen Donoghue, David H. Miller, The UK Antegren Study Group
Neurology. 1999308 Citations
Related on ScholarIQ
University of Liverpool
Institution
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Paper
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
Paper
Achieving Saturation in Thematic Analysis: Development and Refinement of a Codebook
Paper
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Paper
The effect of anti-α4 integrin antibody on brain lesion activity in MS
Paper